Qiming Portfolio Company Yanyin Technology Partners with HEC Pharm on Strategic AI Collaboration
The two parties will engage in in-depth collaboration on AI agent R&D, using the AI translation agent project as a starting point to develop solutions covering core scenarios including experimental design and IND filing, as well as AI laboratory automation robotics. Together, they will explore the deep application of AI technology across the full drug discovery and development pipeline, accelerating the globalization strategy of East Sunshine Pharmaceutical.
Recently, Qiming Venture Partners portfolio company Shanghai YanYin Technology Co., Ltd. ("YanYin Technology") and Guangdong East Sunshine Pharmaceutical Co., Ltd. ("East Sunshine Pharmaceutical") officially announced a strategic partnership. The two parties will collaborate deeply on the development of AI agents, using the AI Translation Agent project as a starting point to develop solutions covering core scenarios including experimental design, IND filing, and AI laboratory automation robotics. Together, they will explore the deep application of AI technology across the full drug R&D workflow, accelerating East Sunshine Pharmaceutical's globalization strategy.
East Sunshine Pharmaceutical is a leading enterprise in China's pharmaceutical industry, a comprehensive pharmaceutical company focused on innovative drug R&D, manufacturing, and commercialization. After more than two decades of development, East Sunshine Pharmaceutical has built independent international-standard R&D platforms and production facilities, with a strong and diversified product portfolio in infectious diseases, chronic diseases, and oncology. The company consistently adheres to independent R&D as its core driving force, and actively applies AI technology at every stage of drug discovery to continuously enhance its innovation capabilities and core competitiveness.
YanYin Technology is China's leading molecular biology research platform, committed to becoming a global leader in AI for R&D Cloud. Its flagship product "YanYin Zhiyan Cloud" is an enterprise-grade biological research collaboration platform based on large AI models. Its "AI Translation Agent" is an intelligent solution purpose-built for the biopharmaceutical sector. It provides one-stop services for the large volume of specialized documentation involved in overseas registration of pharmaceutical products — from intelligent translation and model customization to post-editing and cloud-based collaborative management — precisely addressing industry pain points.
Based on this cooperation, the two parties will engage in long-term strategic partnership and technology integration, aiming to bridge cutting-edge AI technology with real-world business scenarios, improve R&D efficiency, and establish new industry paradigms. This collaboration is not only a powerful testament to YanYin Technology's AI technical capabilities, but also lays a solid foundation for the two parties to deepen cooperation across broader research scenarios in the future.
Jin Chuanfei, Deputy General Manager of Guangdong East Sunshine Pharmaceutical Co., Ltd., stated: "East Sunshine Pharmaceutical engages in the R&D, manufacturing, and sales of Class 1 innovative drugs, with primary focus on three major areas: anti-infection, anti-tumor, and metabolism. We hope to deepen cooperation with YanYin Technology on AI agents and laboratory automation, leveraging AI to empower R&D business scenarios, and strive to create a new benchmark for intelligent biopharmaceutical R&D."
Dr. Chen Zeping, Founder and CEO of YanYin Technology, stated: "We are deeply honored to earn the recognition and trust of an industry benchmark enterprise like East Sunshine Pharmaceutical. Winning out in fierce competition is a strong affirmation of YanYin Technology team's technical capabilities and service philosophy. We will fully support East Sunshine Pharmaceutical's global business, helping enhance its research and operational efficiency with the most cutting-edge AI technology. This is just the beginning — we look forward to joining hands with East Sunshine Pharmaceutical to jointly explore the limitless possibilities of AI in the biopharmaceutical field, and contribute more value to industry development."
Past Highlights
Qiming Stars | YanYin Technology and Zhuanma Bio Jointly Launch China's First CRISPR Gene Design Tool Qiming Perspectives | Qiming Venture Partners' Kan Chen: AI's Transformation of the Biopharmaceutical Industry Is Already Evident Qiming Honors | Qiming Venture Partners and Portfolio Companies Win Multiple Awards at the 2029th Healthcare Investment Excellence Awards
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total committed capital reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, among others.